Medication classes
Biosimilar articles covering lower-cost biologic alternatives, approvals, switching, access, and treatment decisions in IBD. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 2 · 50 articles
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Crohn's disease, and Biosimilars. The original article is from Arquivos de...
Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Adalimumab, Biosimilars, and Anti-TNF. Open the original article for the full details.
The findings suggest people with IBD on IV infliximab could switch to fixed-dose SC infliximab without losing drug exposure, and many may gain convenience and higher trough drug levels regardless of concomitant...
This gives families and clinicians a non‑TNF biologic option on‑label for children aged 2+ with moderate‑to‑severe ulcerative colitis, which can change insurance conversations and expand treatment choices for kids who...
Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
This matters because many patients and clinics face procurement-driven switches from reference biologics to biosimilars; early evidence here suggests short-term outcomes and treatment persistence are similar after...
If you’re stable on ustekinumab for Crohn’s disease, this multicenter study found that switching to an approved biosimilar produced similar 6-month remission and safety outcomes to staying on the original product. That...
This bill could make lower-cost biosimilars more available at the pharmacy counter, potentially reducing out-of-pocket costs and helping people with Crohn’s disease and other conditions stay on prescribed biologic...
Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Natalizumab, and Biosimilars.
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab...
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
New approvals and pipeline activity can expand future treatment options and affect availability, pricing, and research priorities for Crohn’s disease. Market analyses can signal which therapies companies expect to...
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...
New treatment studies and biosimilars could affect future options and access to care. The piece also points out growing pediatric Crohn’s care and supports available (like an infusion center).
Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...
A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...
Cure8 found this source from business-standard.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.
